Daniel Hunting
Family · Idaho Falls, IDNPI 1336710862
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,220 of the $5,930 with a category attached, or 71.2%. 31 manufacturers reported payments, led by Medtronic at 40.3% of the total. Reporting peaked in 2024 at $3,336 and has fallen 67.6% since, to $1,082 in 2025. Among family clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 260 payments — averaging $22.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Novartis$876
- Pfizer$550
- Merck$438
- Lexicon Pharmaceuticals, Inc.$177
- Kiniksa Pharmaceuticals International, PLC$155
- plus $1K from 25 others
What the payments were for
- Travel & lodging$1,71029%
- Food & beverage$4,22071%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 21 | $2,392 |
| Novartis | 86 | $876 |
| Pfizer | 35 | $550 |
| Merck | 25 | $438 |
| Lexicon Pharmaceuticals, Inc. | 8 | $177 |
| Kiniksa Pharmaceuticals International, PLC | 8 | $155 |
| Boston Scientific | 9 | $142 |
| AstraZeneca | 6 | $139 |
| Johnson & Johnson | 8 | $128 |
| Alnylam Pharmaceuticals Inc. | 6 | $108 |
| Daiichi Sankyo Inc. | 6 | $99 |
| Bayer | 5 | $95 |
| Cvrx, Inc. | 7 | $89 |
| Amgen | 5 | $74 |
| Scpharmaceuticals Inc. | 3 | $60 |
| Bridgebio Pharma, Inc. | 2 | $58 |
| Boehringer Ingelheim | 2 | $45 |
| E.r. Squibb & Sons, L.L.C. | 3 | $36 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $35 |
| Inspire Medical Systems, Inc. | 1 | $34 |
| Lilly USA, LLC | 2 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
| Mannkind Corporation | 1 | $23 |
| Sanofi | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Philips North America LLC | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| United Therapeutics Corporation | 1 | $15 |
| Altathera Pharmaceuticals LLC | 1 | $14 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
| Actelion Pharmaceuticals US, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMPLICITY G3$1,285
How this compares
$5,930 in reported general payments places this provider in the 95th percentile of 809 family providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 234 | $280,975 |
| EntrestoSacubitril/Valsartan | 63 | $78,239 |
| XareltoRivaroxaban | 46 | $56,610 |
| FarxigaDapagliflozin Propanediol | 63 | $52,107 |
| Repatha SureclickEvolocumab | 23 | $19,312 |
| Repatha SyringeEvolocumab | 30 | $17,295 |
| Prasugrel Hcl | 44 | $12,533 |
| JardianceEmpagliflozin | 11 | $11,292 |
| Potassium Chloride | 219 | $6,635 |
| Flecainide Acetate | 72 | $5,225 |
| Amiodarone Hcl | 80 | $4,218 |
| Metoprolol Succinate | 291 | $3,685 |
| SotalolSotalol Hcl | 121 | $3,373 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,014 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 21 | $2,957 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $550 | $280,975234 claims |
| NovartisEntresto | $876 | $78,23963 claims |
| Johnson & JohnsonXarelto | $128 | $56,61046 claims |
| AstraZenecaFarxiga, Symbicort | $139 | $55,12174 claims |
| Boehringer IngelheimJardiance | $45 | $11,29211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 809 family providers in Idaho.
Other family in Idaho Falls
- Amber MasseIdaho Falls$17K
- Samantha de Bruyn KopsIdaho Falls$10K
- Paula SanderlinIdaho Falls$10K
- Sunita SigdelIdaho Falls$9K
- Melissa KellyIdaho Falls$7K
- Kelsi RoundsIdaho Falls$6K
- Sunny RaichartIdaho Falls$5K
- Derek WhitmillIdaho Falls$5K
- Malinda McReaIdaho Falls$5K
- Jonathan WilliamsIdaho Falls$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.